Rabie M, Shaker NM, Gaber E, El-Habiby M, Ismail D, El-Gaafary M, et al. Prevalence updates of substance use among Egyptian adolescents. MECP. 2020;27:4.

Google Scholar 

Kabbash I, Zidan O, Saied S. Substance abuse among university students in Egypt: prevalence and correlates. East Mediterr Health J. 2022;28(1):31–40.

Article  PubMed  Google Scholar 

Yeruva R, Mekala H, Lippmann S, Lippmann S. Synthetic cannabinoids-“spice” can induce a psychosis: a brief review. Innov Clin Neurosci. 2019;16(1–2):31–2.

PubMed  PubMed Central  Google Scholar 

Sobh ZK and Sobh HK. Strox (Novel Synthetic Cannabinoids) in Egypt: Medical and Legal Challenges, Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, University of Alexandria, Egypt and Ministry of Health, Egypt; 2020.

Oberbarnscheid CT, Miller NS. The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res. 2020;12(7):393–403.

Article  Google Scholar 

Department of Justice, Cairo. Voodoo and Strox: the synthetic drugs wreaking havoc in Cairo; 2018: access: 23/07/2018–13:22. https://observers.france24.com/en/20180723-voodoo-strox-drugs-cairo-egypt.

Hess C. Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol. 2016;34:329–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.

Article  CAS  PubMed  Google Scholar 

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, et al. Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013;233:416–22.

Article  CAS  PubMed  Google Scholar 

Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350(1):59–62.

Article  PubMed  Google Scholar 

Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzieblo A, Dobrowolski PJ, et al. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem. 2011;83:6381.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hutter M, Moosmann B, Kneisel S, Auwärter V. Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM-2201 regarding its chemistry and metabolism. J Mass Spectrum. 2013;48:885.

Article  CAS  Google Scholar 

Jang M, Yang W, Shin I, Choi H, Chang H, Kim E. Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse. Int J Legal Med. 2014;128:285.

Article  PubMed  Google Scholar 

Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73:292–7.

Article  Google Scholar 

Radhakrishnan R, Wilkinson S, D’Souza D. Gone to pot–a review of the association between cannabis and psychosis. Front Psychiatry. 2014;5:54.

Article  PubMed  PubMed Central  Google Scholar 

McKeever R, Vearrier D, Jacobs D, LaSala G, Okaneku J, Greenberg MI. K2-Not the spice of Life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol. 2015;11:129–31.

Article  PubMed  Google Scholar 

Schep L, Slaughter R, Hudson S, Place R, Watts M. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 2015;34:557–60.

Article  CAS  PubMed  Google Scholar 

Shanks K, Dahn T, Terrell A. Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol. 2012;36:145–52.

Article  CAS  PubMed  Google Scholar 

Nacca N, Vatti D, Sullivan R. The synthetic cannabinoid withdrawal syndrome. J Addict Med. 2013;7:296–8.

Article  CAS  PubMed  Google Scholar 

Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, et al. Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med. 2014;128:59.

Article  PubMed  Google Scholar 

Tomiyama K, Funada M. Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol. 2014;274:17–23.

Article  CAS  PubMed  Google Scholar 

Miller R, Thakur G, Stewart W, Bow JP, Bajaj S, Makriyannis A, et al. Effects of a novel CB1 agonist on visual attention in male rats: Role of strategy and expectancy in task accuracy. Exp Clin Psychopharmacol. 2013;21:416–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basavarajappa B, Subbanna S. CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus. 2014;24(2):178–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lazarov O, Hollands C. Hippocampal neurogenesis: learning to remember. Prog Neurobiol. 2016;138–140:1–18.

Article  PubMed  PubMed Central  Google Scholar 

Cohen K, Weinstein A. The effects of cannabinoids on executive functions: evidence from cannabis and synthetic cannabinoids-a systematic review. Brain Sci. 2018;8(3):40.

Article  PubMed  PubMed Central  Google Scholar 

Hill SY, Wang S, Carter H, McDermott MD, Zezza N, Stiffler S. Amygdala volume in offspring from multiplex for alcohol dependence families: the moderating influence of childhood environment and 5-HTTLPR variation. J Alcohol Drug Depend. 2013; Suppl 1:001.

First MB, Spitzer RL, Williams W, Gibbon M. Structured clinical interview for DSM-IV axis I disorders (SCID-I). In: Rush AJ, First MB, Blacker D, editors. Handbook of psychiatric measures. Washington: American Psychiatric Association; 1995.

Google Scholar 

Missiry A, Sorour A, Sadek A, Fahy T, Mawgoud M and Asaad A. Homicide and psychiatric illness: an Egyptian study [MD thesis]. Cairo, Egypt; Faculty of Medicine, Ain Shams University; 2004.

First MB, Gibbon M, Williams J, Benjamine LS. Structured clinical interview for DSM-IV axis II Personality Disorders (SCID II). Washington: American Psychiatric Press; 1997.

Google Scholar 

Hatata H, Khalil A, Asaad T, Abo Zeid M, Okasha T. Dual diagnosis in substance use disorders (MD thesis). Faculty of Medicine, Ain Shams University, Cairo, Egypt; 2004.

McLellan AT, Luborsky L, O’Brien CP, Woody GE. An improved diagnostic instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.

Article  CAS  PubMed  Google Scholar 

Qasem T, Beshry Z, Asaad T. Profiles of Neuropsychological Dysfunction in Chronic Heroine Users. MD degree thesis. Faculty of Medicine. Ain Shams University; 2003.

Benton AL. Revised Visual Retention Test: clinical and experimental applications. 4th ed. New York: Psychological Corporation; 1974.

Google Scholar 

Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–6.

Article  Google Scholar 

Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: theory and clinical interpretation. South Tucson: Neuropsychology Press; 1985.

Google Scholar 

Rabin LA, Barr WB, Butler LA. Assessment practices of clinical neuropsychologists in the United States and Canada: a survey of INS, NAN, APA Division 40 members. Arch Clin Neuropsych. 2005;20:33–65.

Article  Google Scholar 

Axelrod BN. Administration duration for the Wechsler Adult Intelligence, Scale-III and Wechsler Memory Scale-III. Arch Clin Neuropsychol. 2001;16:293–301.

Article  CAS  PubMed  Google Scholar 

Hackman DA, Farah MJ. Socioeconomic status and the developing brain. Trends Cogn Sci. 2009;13(2):65–73.

Article  PubMed  PubMed Central  Google Scholar 

Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30(12):1321–30.

Article  PubMed  Google Scholar 

Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs. 2014;19:119–26.

Article  PubMed  Google Scholar 

Goretti S, Sanchez MDC, Borja PL, Rivera GB, Rodríguez L. The relationship between personality disorders and substance abuse disorders. Eur Psychiat. 2017;41:473–4.

Article  Google Scholar 

Drake RE, O’Neal EL, Wallach MA. A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2012;34:123–38.

Article  Google Scholar 

Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep. 2016;18(5):52.

Article  PubMed  PubMed Central  Google Scholar 

Hopkins CY, Gilchrist BL. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med. 2013;45:544–6.

Article  PubMed  Google Scholar 

Sevinc MM, Kinaci E, Bayrak S, Yardimci AH, Cakar E. Extraordinary cause of acute gastric dilatation and hepatic portal venous gas: chronic use of synthetic cannabinoid. World J Gastroenterol. 2015;21:10704–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takematsu M, Hoffman RS, Nelson LS, Schechter JM, Moran JH. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol. 2014;52:973–5.

Article  CAS  Google Sc